Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

January 14, 2008

Primary Completion Date

April 28, 2020

Study Completion Date

October 28, 2022

Conditions
NeuroblastomaMedulloblastoma
Interventions
DRUG

Nifurtimox

30mg/kg/day PO divided into TID dosing q day

DRUG

Cyclophosphamide

250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.

DRUG

Topotecan

0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.

Trial Locations (15)

17033

Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey

28204

Levine Children's Hospital, Charlotte

29425

Medical University of South Carolina, Charleston

32806

Arnold Palmer Hospital for Children- MD Anderson, Orlando

49503

Helen DeVos Children's Hospital, Grand Rapids

55404

Children's Hospital and Clinics on Minnesota, Minneapolis

63104

Cardinal Glennon Children's Medical Center, St Louis

64108

Children's Mercy Hospitals and Clinics, Kansas City

75235

Children's Medical Center, Dallas

77030

Texas Children's Cancer and Hematology Centers, Houston

84113

Primary Children's Hospital, Salt Lake City

92123

Rady Children's Hospital, San Diego

96813

Kapiolani Medical Center for Women and Children, Honolulu

06106

Connecticut Children's Hospital, Hartford

02111

Tufts Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Giselle Sholler

OTHER